Bryan Ball - Aadi Bioscience Chief Operations
| AADI Stock | USD 2.30 0.02 0.88% |
Insider
Bryan Ball is Chief Operations of Aadi Bioscience
| Age | 54 |
| Address | 17383 Sunset Boulevard, Pacific Palisades, CA, United States, 90272 |
| Phone | 424 744 8055 |
| Web | https://aadibio.com |
Bryan Ball Latest Insider Activity
Tracking and analyzing the buying and selling activities of Bryan Ball against Aadi Bioscience stock is an integral part of due diligence when investing in Aadi Bioscience. Bryan Ball insider activity provides valuable insight into whether Aadi Bioscience is net buyers or sellers over its current business cycle. Note, Aadi Bioscience insiders must abide by specific rules, including filing SEC forms every time they buy or sell Aadi Bioscience'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Bryan Ball over six months ago Disposition of 20000 shares by Bryan Ball of Aadi Bioscience subject to Rule 16b-3 |
Aadi Bioscience Management Efficiency
The company has return on total asset (ROA) of (0.3527) % which means that it has lost $0.3527 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6595) %, meaning that it created substantial loss on money invested by shareholders. Aadi Bioscience's management efficiency ratios could be used to measure how well Aadi Bioscience manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.52. The current Return On Capital Employed is estimated to decrease to -0.71. As of now, Aadi Bioscience's Other Current Assets are increasing as compared to previous years. The Aadi Bioscience's current Non Current Assets Total is estimated to increase to about 8.2 M, while Intangible Assets are projected to decrease to under 3 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Jack Anders | Revolution Medicines | 47 | |
| Path FRCP | Revolution Medicines | 61 | |
| Robyn Sweinhart | Rezolute | N/A | |
| Dawn Giangiulio | Design Therapeutics | N/A | |
| Troy JD | Kura Oncology | 55 | |
| David Pompliano | Revolution Medicines | N/A | |
| Sean Jeffries | Design Therapeutics | 44 | |
| Erick MD | Acrivon Therapeutics, Common | 66 | |
| Jonathan MD | Erasca Inc | 52 | |
| Eric Easom | AN2 Therapeutics | 56 | |
| Jesper Olsen | Acrivon Therapeutics, Common | N/A | |
| John II | Ultragenyx | 58 | |
| Crystal Mercado | Acrivon Therapeutics, Common | N/A | |
| Filip MD | Monte Rosa Therapeutics | 50 | |
| Joo MD | Design Therapeutics | 61 | |
| Jc MD | Adagene | 59 | |
| John Castle | Monte Rosa Therapeutics | 53 | |
| Nik Chetwyn | Erasca Inc | N/A | |
| Kristina Masson | Acrivon Therapeutics, Common | 44 | |
| Kenneth Cundy | Anebulo Pharmaceuticals | 65 | |
| MD FACP | AN2 Therapeutics | 76 | |
Management Performance
| Return On Equity | -0.66 | ||||
| Return On Asset | -0.35 |
Aadi Bioscience Leadership Team
Elected by the shareholders, the Aadi Bioscience's board of directors comprises two types of representatives: Aadi Bioscience inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Aadi. The board's role is to monitor Aadi Bioscience's management team and ensure that shareholders' interests are well served. Aadi Bioscience's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Aadi Bioscience's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Neil Desai, President, Founder | ||
| Raymond Steitz, Senior Officer | ||
| Bryan Ball, Chief Operations | ||
| David Lennon, CEO President | ||
| Marcy Graham, SVP Communications | ||
| Stephen JD, Senior Counsel | ||
| Brendan MBA, Chief Officer | ||
| MD FACP, Chief Officer | ||
| Scott CPA, Treasurer, CFO |
Aadi Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Aadi Bioscience a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.66 | ||||
| Return On Asset | -0.35 | ||||
| Profit Margin | (2.46) % | ||||
| Operating Margin | (1.49) % | ||||
| Current Valuation | (4.98 M) | ||||
| Shares Outstanding | 24.65 M | ||||
| Shares Owned By Insiders | 9.96 % | ||||
| Shares Owned By Institutions | 49.06 % | ||||
| Number Of Shares Shorted | 281.12 K | ||||
| Price To Book | 0.82 X |
Currently Active Assets on Macroaxis
When determining whether Aadi Bioscience offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Aadi Bioscience's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Aadi Bioscience Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Aadi Bioscience Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aadi Bioscience. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. For more detail on how to invest in Aadi Stock please use our How to Invest in Aadi Bioscience guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aadi Bioscience. If investors know Aadi will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aadi Bioscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.28) | Revenue Per Share 0.929 | Quarterly Revenue Growth 0.21 | Return On Assets (0.35) | Return On Equity (0.66) |
The market value of Aadi Bioscience is measured differently than its book value, which is the value of Aadi that is recorded on the company's balance sheet. Investors also form their own opinion of Aadi Bioscience's value that differs from its market value or its book value, called intrinsic value, which is Aadi Bioscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aadi Bioscience's market value can be influenced by many factors that don't directly affect Aadi Bioscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aadi Bioscience's value and its price as these two are different measures arrived at by different means. Investors typically determine if Aadi Bioscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aadi Bioscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.